Lilly’s Protomer deal shows innovation in diabetes is not dead
Lilly and Novo look set for a battle in glucose-sensitive insulin, and other areas too.
Medtech gears up for a vintage acquisition year
Device deal making is back in a big way, despite the munificence of venture funds.
Spac listings slow as the hunt for deals continues
Spacs still have their supporters, but SEC scrutiny and mixed post-deal performance mean that the story is losing its lustre.
Why Glaxo should buy Biohaven
And four other potential targets that could make sense for the beleaguered group.
Biopharma takeovers dry up
If the first quarter was quiet for takeovers the second saw M&A grind to a halt. What can the matter be?
